Department of Vascular Surgery, University Hospital Leipzig, Leipzig, Germany.
Department of Vascular Surgery, University Hospital Leipzig, Leipzig, Germany.
Eur J Vasc Endovasc Surg. 2021 Mar;61(3):407-412. doi: 10.1016/j.ejvs.2020.10.023. Epub 2020 Nov 30.
The aim was to describe the outcomes of high risk patients with symptomatic or contained rupture of pararenal (PRAs) and thoraco-abdominal aortic aneurysms (TAAAs) with anatomy unsuitable for commercially available stent grafts who underwent fenestrated endovascular aneurysm repair (FEVAR) using physician modified stent grafts (PMSGs) planned with 3D image analysis software (3DIMAS), and 3D printed aortic models (3DAMs).
Nineteen consecutive patients (17 male; mean age, 70 ± 9 years) underwent PMSG-FEVAR between 2015 and 2019. 3DAMs to plan the PMSGs were introduced in 2018. End points were all cause mortality, freedom from any endoleak, target vessel patency, and re-intervention.
Seven patients (36.8%) were treated with PMSGs using 3DIMAS (three PRAs, three type IV, and one type III TAAAs), and 12 patients (63.2%) received PMSGs using 3DAMs (five PRAs, seven type IV TAAAs). Six patients presented with contained aortic rupture and 13 patients were treated for symptomatic aortic aneurysm. Mean aortic diameter was 72 ± 10 mm. The choice of stent graft for fenestration was the Valiant Captivia Closed Web (Medtronic), except for one patient. Sixteen (84.2%) stent grafts were manufactured with four fenestrations. Technical success was 100%. Seventy-one renovisceral branch vessels were targeted with fenestrations. Mean length of hospital stay was 17.3 ± 10.4 days. Thirty day mortality was 0%. Two patients developed reversible spinal cord injury. Mean follow up was 14.4 months (range 1-52 months). During follow up one non-aneurysm related death occurred, and two successful re-interventions were performed: one to re-establish renal artery patency, and one to treat a type 1c endoleak.
PMSGs for urgent treatment of pararenal and thoraco-abdominal aortic aneurysms in high risk patients unsuitable for commercially available stent grafts are feasible and safe. 3D printing technology may improve urgent construction of patient specific devices for treatment of complex aortic pathologies and improve outcomes.
描述使用医师定制支架移植物(PMSG)并结合 3D 图像分析软件(3DIMAS)和 3D 打印主动脉模型(3DAM)行开窗腔内血管修复术(FEVAR)治疗不适合使用市售支架移植物的高危症状性或局限性破裂的腹膜后(PRAs)和胸腹主动脉瘤(TAAAs)患者的结局。
2015 年至 2019 年,19 例连续患者(17 例男性;平均年龄 70±9 岁)接受 PMSG-FEVAR 治疗。2018 年引入 3DAM 来规划 PMSG。终点为全因死亡率、无任何内漏、靶血管通畅率和再干预率。
7 例(36.8%)患者使用 3DIMAS 行 PMSG-FEVAR(3 例 PRAs、3 例 IV 型和 1 例 III 型 TAAAs),12 例(63.2%)患者使用 3DAM 行 PMSG-FEVAR(5 例 PRAs、7 例 IV 型 TAAAs)。6 例患者为局限性主动脉破裂,13 例患者为症状性主动脉瘤。平均主动脉直径为 72±10mm。开窗用支架移植物的选择为 Valian Captivia 封闭式网管(美敦力),除 1 例外。16 个(84.2%)支架移植物制造 4 个开窗。技术成功率为 100%。71 个内脏分支血管被定位进行开窗。平均住院时间为 17.3±10.4 天。30 天死亡率为 0%。2 例发生可逆性脊髓损伤。平均随访 14.4 个月(1-52 个月)。随访期间,1 例与非动脉瘤相关的死亡,2 例成功进行再干预:1 例再通肾动脉,1 例治疗 1c 型内漏。
对于不适合使用市售支架移植物的高危症状性或局限性破裂的腹膜后和胸腹主动脉瘤患者,紧急使用医师定制支架移植物是可行且安全的。3D 打印技术可能会提高针对复杂主动脉病变的个体化治疗设备的紧急构建能力,并改善结局。